#BEGIN_DRUGCARD DB03530

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C17H19N5O7S2

# Chemical_IUPAC_Name:
(2S)-2-[(1R)-1-[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetamido]-2-oxoethyl]-5-methylidene-5,6-dihydro-2H-1,3-thiazine-4-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Acylated Ceftazidime

# HET_ID:
CAZ

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C17H19N5O7S2/c1-7-5-30-13(21-10(7)14(25)26)8(4-23)19-12(24)11(9-6-31-16(18)20-9)22-29-17(2,3)15(27)28/h4,6,8,13H,1,5H2,2-3H3,(H2,18,20)(H,19,24)(H,25,26)(H,27,28)/b22-11+/t8-,13+/m1/s1

# InChI_Key:
InChIKey=VEHPZKIFULQYFS-BQFDAFGASA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3530

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
469.492

# Molecular_Weight_Mono:
469.072589367

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1IEL

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
0.37

# Predicted_LogS:
-4.1

# Predicted_Water_Solubility:
3.79e-02 g/l

# Primary_Accession_No:
DB03530

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936705

# PubChem_Substance_ID:
46508439

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00836

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
O=C[C@@H](NC(=O)C(=N\OC(C)(C)C(O)=O)\C1=CSC(N)=N1)[C@@H]1SCC(=C)C(=N1)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:21 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cell membrane
multi-pass membrane protein (Probable)

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X52734

# Drug_Target_1_GenBank_ID_Protein:
46758

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
blaR1

# Drug_Target_1_Gene_Sequence:
>1758 bp
TTATTGGCCATTTAAAACACCCATTTCTTTTAATATTTTTTCACTGATTAATTCAGCATT
TTTCCCAGATGGCTTTCCATCTGATAAATGTGTAGCAAAATAATACTTATCATGATTTGT
AATTACGTAACCTACAAACCACCCATTATTATACTTCCCGTTTACTATACCTGTACCTGT
TTTCCCATACAGTTCATACTTTTCATTTTTCTTAATCAATAATGAAGAAGATAATTGATT
CTTTGCTTTTTTACTAAAATGGTTATTTTGTTCCATCATATTTTTAAAAACTATTACTTG
TTCAAGATTAGATATTTTCAAACTATCTTCCATCCAATAGCTTTTATAACTTCCCAAATT
TTTATTACCATAATTTAATTGCTTGAGTTGAGTCGCAGTATAGTTCTTTGGTATTTGATC
GCTAATACGTTCGAAGTACCAATTAACTGAATTTTGCATTGCTGTATTTAAATCTTGTTC
CTTATTCCAAGCATCAAAAGGGTAATGCTTATGATTCCATGACATACGTGAATTTTCATC
ATTTATAATATGTCGGTCAAGTCCAAACATAGCTAAATAAATTTTATAAGTTGAATTAGG
AGAATACCTTTTTCTACTTTCTTTTTCGTTATAAATATAGTATTTGTCTTTCTTCATGCT
GTACATGACGAAAGATCCACTATTTGAACCAAAAATTTTACTTTTATCTAAAATTTGGTA
ATCGTTGTGTAAGGGCTTTTTATAATTATAATCAGTTATGGATTGCCCCATCAAAAACTG
GCTTTGAATTACCATGAGCAAAAAAGTAAAAATACAAATAAAAATTAGAATTAATTTGGA
CTGTTTTTTCAGATTGGCTTCTTTTATATTAATTAATCTTCTTTTGAGTAATGACTTTTT
ACCATTAAATGAATGGCTTAATATATTTTTATTAAAAAATGGAACATTTAATACGGAGTC
CATAATAGATTCCGCATAAGTTTTAAATTCATTTTTGTTAATATTATTAAGGACAAATCT
ATCGGCTTCTACTTCATTGTCATGAATTATCTTTCTTTTTACAATATGTACTAATGGATT
GTAACTCATAATAATAGAGAAGATATTAAAGATAATTAAATGTAAAGTATCTCTATTTTT
AGCATGAGCATATTCATGCAATATTATATATTTTAGTCTTTTGTCAATTACACTTTTAAA
ATATGAACTAGGAATCAAAATAATATATTTCCCATACCAAAAAGTTATTGGAGATTGAAT
AGTCTCTGCTTTTCGAATCACAATATTTTTTTTATATTGATGGTTGAAAAGTATCGTATC
TATTTTATTTTTTTCATTTTCGTTTAGATAAAGTGACTGTTTCTTTAAATATTTAAGATA
TAATAAGGCTTTCAAAAATTTAAAACTTAAAATAATAACTAAAACTATCCAAATAACTGT
GCTGATATTATCAATTGAATCCCAATTAAACTTATGGATATCTGTTGCGAACTCTTGAAT
AGGTTTGGTGGTATTTATGTTATGGTTCAAGTCGTGTGACTTACTTTCAACTGTGGGCGC
TTGATTATTCACATTATTAAATTTAAAAAGAGAGAATTTAATAGGAATGAAAGGAATTAA
TCCTGCAAGAAGAGTTAGATACCAAACTTTATAATTTAACATATAATTAAAATAGCGTTT
TAATATGTACCTAAAAAATAATAACAATAGAAATATAAAACAAAAGCTTACTATGCTCAT
TATTAATAACTTAGCCAT

# Drug_Target_1_General_Function:
Defense mechanisms and antibiotic binding

# Drug_Target_1_General_References:
2170815	Rowland SJ, Dyke KG: Tn552, a novel transposable element from Staphylococcus aureus. Mol Microbiol. 1990 Jun;4(6):961-75.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3010

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
69246

# Drug_Target_1_Name:
Regulatory protein blaR1

# Drug_Target_1_Number_of_Residues:
585

# Drug_Target_1_PDB_ID:
1XA1

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00905	Transpeptidase
PF05569	Peptidase_M56

# Drug_Target_1_Protein_Sequence:
>Regulatory protein blaR1
MAKLLIMSIVSFCFIFLLLLFFRYILKRYFNYMLNYKVWYLTLLAGLIPFIPIKFSLFKF
NNVNNQAPTVESKSHDLNHNINTTKPIQEFATDIHKFNWDSIDNISTVIWIVLVIILSFK
FLKALLYLKYLKKQSLYLNENEKNKIDTILFNHQYKKNIVIRKAETIQSPITFWYGKYII
LIPSSYFKSVIDKRLKYIILHEYAHAKNRDTLHLIIFNIFSIIMSYNPLVHIVKRKIIHD
NEVEADRFVLNNINKNEFKTYAESIMDSVLNVPFFNKNILSHSFNGKKSLLKRRLINIKE
ANLKKQSKLILIFICIFTFLLMVIQSQFLMGQSITDYNYKKPLHNDYQILDKSKIFGSNS
GSFVMYSMKKDKYYIYNEKESRKRYSPNSTYKIYLAMFGLDRHIINDENSRMSWNHKHYP
FDAWNKEQDLNTAMQNSVNWYFERISDQIPKNYTATQLKQLNYGNKNLGSYKSYWMEDSL
KISNLEQVIVFKNMMEQNNHFSKKAKNQLSSSLLIKKNEKYELYGKTGTGIVNGKYNNGW
FVGYVITNHDKYYFATHLSDGKPSGKNAELISEKILKEMGVLNGQ

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
BlaR1 is a potential penicillin-binding protein required for induction of beta-lactamase

# Drug_Target_1_SwissProt_ID:
P18357

# Drug_Target_1_SwissProt_Name:
BLAR_STAAU

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
10.12

# Drug_Target_1_Transmembrane_Regions:
4-22
38-58
108-128
214-233
309-330

# Drug_Target_2_Cellular_Location:
Periplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
J01611

# Drug_Target_2_GenBank_ID_Protein:
145267

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
ampC

# Drug_Target_2_Gene_Sequence:
>1134 bp
ATGTTCAAAACGACGCTCTGCGCCTTATTAATTACCGCCTCTTGCTCCACATTTGCTGCC
CCTCAACAAATCAACGATATTGTGCATCGCACAATTACCCCGCTTATAGAGCAACAAAAG
ATCCCGGGTATGGCGGTGGCGGTAATTTATCAGGGTAAACCTTATTACTTTACCTGGGGC
TATGCGGACATCGCCAAAAAGCAGCCCGTCACACAGCAAACGTTGTTTGAGTTAGGTTCG
GTCAGCAAAACATTTACTGGCGTGCTTGGTGGCGACGCTATTGCTCGAGGGGAAATCAAG
TTAAGCGATCCCACAACAAAATACTGGCCTGAACTTACCGCTAAACAGTGGAATGGGATC
ACACTATTACATCTCGCAACCTACACTGCTGGCGGCCTGCCATTGCAGGTGCCGGATGAG
GTGAAATCCTCAAGCGACTTGCTGCGCTTCTATCAAAACTGGCAGCCTGCATGGGCTCCA
GGAACACAACGTCTGTATGCCAACTCCAGTATCGGTTTGTTCGGCGCACTGGCTGTGAAG
CCGTCTGGTTTGAGTTTTGAGCAGGCGATGCAAACTCGTGTCTTCCAGCCACTCAAACTC
AACCATACGTGGATTAATGTACCGCCCGCAGAAGAAAAGAATTACGCCTGGGGATATCGC
GAAGGTAAGGCAGTGCATGTTTCGCCTGGGGCGTTAGATGCTGAAGCTTATGGTGTGAAG
TCGACCATTGAAGATATGGCCCGCTGGGTGCAAAGCAATTTAAAACCCCTTGATATCAAT
GAGAAAACGCTTCAACAAGGGATACAACTGGCACAATCTCGCTACTGGCAAACCGGCGAT
ATGTATCAGGGCCTGGGCTGGGAAATGCTGGACTGGCCGGTAAATCCTGACAGCATCATT
AACGGCAGTGACAATAAAATTGCACTGGCAGCACGCCCCGTAAAAGCGATTACGCCCCCA
ACTCCTGCAGTACGCGCATCATGGGTACATAAAACAGGGGCGACCGGCGGATTTGGTAGC
TATGTCGCGTTTATTCCAGAAAAAGAGCTGGGTATCGTGATGCTGGCAAACAAAAACTAT
CCCAATCCAGCGAGAGTCGACGCCGCCTGGCAGATTCTTAACGCTCTACAGTAA

# Drug_Target_2_General_Function:
Defense mechanisms and antibiotic degradation

# Drug_Target_2_General_References:
10595535	Powers RA, Blazquez J, Weston GS, Morosini MI, Baquero F, Shoichet BK: The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase. Protein Sci. 1999 Nov;8(11):2330-7.
11478888	Powers RA, Caselli E, Focia PJ, Prati F, Shoichet BK: Structures of ceftazidime and its transition-state analogue in complex with AmpC beta-lactamase: implications for resistance mutations and inhibitor design. Biochemistry. 2001 Aug 7;40(31):9207-14.
12144785	Beadle BM, Shoichet BK: Structural bases of stability-function tradeoffs in enzymes. J Mol Biol. 2002 Aug 9;321(2):285-96.
12526668	Morandi F, Caselli E, Morandi S, Focia PJ, Blazquez J, Shoichet BK, Prati F: Nanomolar inhibitors of AmpC beta-lactamase. J Am Chem Soc. 2003 Jan 22;125(3):685-95.
6795623	Jaurin B, Grundstrom T: ampC cephalosporinase of Escherichia coli K-12 has a different evolutionary origin from that of beta-lactamases of the penicillinase type. Proc Natl Acad Sci U S A. 1981 Aug;78(8):4897-901.
7041115	Grundstrom T, Jaurin B: Overlap between ampC and frd operons on the Escherichia coli chromosome. Proc Natl Acad Sci U S A. 1982 Feb;79(4):1111-5.
7610040	Burland V, Plunkett G 3rd, Sofia HJ, Daniels DL, Blattner FR: Analysis of the Escherichia coli genome VI: DNA sequence of the region from 92.8 through 100 minutes. Nucleic Acids Res. 1995 Jun 25;23(12):2105-19.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9819201	Usher KC, Blaszczak LC, Weston GS, Shoichet BK, Remington SJ: Three-dimensional structure of AmpC beta-lactamase from Escherichia coli bound to a transition-state analogue: possible implications for the oxyanion hypothesis and for inhibitor design. Biochemistry. 1998 Nov 17;37(46):16082-92.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
2478

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
41556

# Drug_Target_2_Name:
Beta-lactamase

# Drug_Target_2_Number_of_Residues:
377

# Drug_Target_2_PDB_ID:
1XGJ

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00144	Beta-lactamase

# Drug_Target_2_Protein_Sequence:
>Beta-lactamase precursor
MFKTTLCALLITASCSTFAAPQQINDIVHRTITPLIEQQKIPGMAVAVIYQGKPYYFTWG
YADIAKKQPVTQQTLFELGSVSKTFTGVLGGDAIARGEIKLSDPTTKYWPELTAKQWNGI
TLLHLATYTAGGLPLQVPDEVKSSSDLLRFYQNWQPAWAPGTQRLYANSSIGLFGALAVK
PSGLSFEQAMQTRVFQPLKLNHTWINVPPAEEKNYAWGYREGKAVHVSPGALDAEAYGVK
STIEDMARWVQSNLKPLDINEKTLQQGIQLAQSRYWQTGDMYQGLGWEMLDWPVNPDSII
NGSDNKIALAARPVKAITPPTPAVRASWVHKTGATGGFGSYVAFIPEKELGIVMLANKNY
PNPARVDAAWQILNALQ

# Drug_Target_2_Reaction:
a beta-lactam + H2O = a substituted beta-amino acid

# Drug_Target_2_Signals:
1-19

# Drug_Target_2_Specific_Function:
This protein is a serine beta-lactamase with a substrate specificity for cephalosporins

# Drug_Target_2_SwissProt_ID:
P00811

# Drug_Target_2_SwissProt_Name:
AMPC_ECOLI

# Drug_Target_2_Synonyms:
Beta-lactamase precursor
Cephalosporinase
EC 3.5.2.6

# Drug_Target_2_Theoretical_pI:
9.07

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB03530
